Compounds > plumbagin
Page last updated: 2024-08-21

plumbagin and Bone Cancer

plumbagin has been researched along with Bone Cancer in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bu, W; Cui, Z; Fan, Q; Han, X; He, XP; Ji, D; Qiao, H; Qin, A; Tang, T; Wang, T; Wang, Y; Yang, S; Yang, Y1
Chao, CC; Chen, PC; Hou, CH; Hou, SM; Huang, CC; Liu, JF1
Du, L; Fan, QM; Li, HW; Tang, TT; Wang, TY; Xu, JK; Yan, W; Zhai, ZJ1
Aggarwal, BB; Oyajobi, B; Sung, B1
Cai, X; Guo, W; Li, W; Li, Z; Lin, Z; Liu, M; Luo, J; Wu, X; Xiao, J; Xie, J; Xu, L; Yang, Z1

Other Studies

5 other study(ies) available for plumbagin and Bone Cancer

ArticleYear
Targeting Osteocytes to Attenuate Early Breast Cancer Bone Metastasis by Theranostic Upconversion Nanoparticles with Responsive Plumbagin Release.
    ACS nano, 2017, 07-25, Volume: 11, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Female; Gadolinium; Humans; Luminescent Agents; Mice; Mice, Nude; Nanoparticles; Naphthoquinones; Optical Imaging; Osteocytes; Silicon Dioxide; Theranostic Nanomedicine; Zoledronic Acid

2017
Plumbagin induces apoptosis in human osteosarcoma through ROS generation, endoplasmic reticulum stress and mitochondrial apoptosis pathway.
    Molecular medicine reports, 2017, Volume: 16, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Calcium; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum Stress; Humans; Mitochondria; Models, Biological; Naphthoquinones; Osteosarcoma; Reactive Oxygen Species; Signal Transduction

2017
Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice.
    Acta pharmacologica Sinica, 2014, Volume: 35, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthoquinones; Osteoclasts; Tumor Microenvironment

2014
Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line; Cell Line, Tumor; Female; Humans; I-kappa B Proteins; Macrophages; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthoquinones; NF-kappa B; NF-KappaB Inhibitor alpha; Osteoclasts; Osteogenesis; Osteolysis; RANK Ligand; Signal Transduction; Xenograft Model Antitumor Assays

2012
Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
    Current molecular medicine, 2012, Volume: 12, Issue:8

    Topics: Actins; Animals; Antigens, Differentiation; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Survival; Cytokines; Enzyme Activation; Female; Gene Expression; Humans; Inhibitory Concentration 50; Macrophages; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Naphthoquinones; Neoplasm Invasiveness; NF-kappa B; Osteoclasts; Osteolysis; Protein Binding; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; TNF Receptor-Associated Factor 6; Tumor Microenvironment; Xenograft Model Antitumor Assays

2012